RedHill Biopharma Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price; Faces 180-Day Compliance Period

summarizeSummary

RedHill Biopharma received a Nasdaq delisting notice due to its stock trading below the $1.00 minimum bid price, initiating a 180-day period to regain compliance.

check_boxKey Events

• Nasdaq Delisting Notice Received

  On April 8, 2026, RedHill Biopharma Ltd. received a letter from Nasdaq's Listings Qualifications Department.

• Non-Compliance with Minimum Bid Price

  The notice indicates the company's American Depositary Shares (ADSs) closed below the minimum $1.00 per share requirement for 30 consecutive business days (February 20, 2026, to April 2, 2026).

• 180-Day Compliance Period

  RedHill has an initial period of 180 calendar days, until October 5, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2).

• Regaining Compliance

  Compliance can be achieved if the ADSs close at $1.00 or more for a minimum of ten consecutive business days before the deadline.

auto_awesomeAnalysis

RedHill Biopharma has received a formal notice from Nasdaq regarding its failure to maintain the minimum $1.00 bid price requirement. This is a critical event as continued non-compliance could lead to delisting, severely impacting the company's liquidity and access to capital markets. While the company has 180 days to regain compliance, the notice itself signals significant operational and financial challenges, especially for a company with a small market capitalization. Investors should monitor the stock price performance closely and any strategic actions the company may take to address this deficiency, such as a reverse stock split.